PROCEPT BioRobotics

PROCEPT BioRobotics specializes in Aquablation therapy, a minimally invasive and heat-free robotic treatment designed for addressing lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation therapy uniquely combines cystoscopic visualization with ultrasound imaging to provide a comprehensive, multidimensional view of the prostate. This therapy is delivered through the AquaBeam Robotic System, which uses a robotically controlled, heat-free waterjet for precise and efficient removal of prostate tissue. Notably, Aquablation therapy is the first and only image-guided, heat-free robotic therapy for BPH, supported by nine clinical trials that demonstrate its effectiveness, safety, and durability. The AquaBeam Robotic System is the first FDA-cleared surgical robot that employs automated tissue resection for treating LUTS due to BPH, ensuring consistent outcomes regardless of prostate size, shape, or surgeon experience. The system integrates real-time, multidimensional imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation. Aquablation therapy has low rates of irreversible complications such as erectile dysfunction, ejaculatory dysfunction, and incontinence, and is covered by Medicare, Medicare Advantage, Tricare, and many commercial insurance plans when medical criteria are met. The AquaBeam Robotic System is intended for the resection and removal of prostate tissue in males suffering from LUTS due to BPH and is protected by multiple patents in the United States and other jurisdictions. The system enables rapid resection times that are consistent and reproducible across all prostate sizes and shapes. Aquablation therapy has been proven effective and safe for both large (80-150 cc) and smaller prostates, typically performed in the operating room under spinal or general anesthesia with an overnight stay.